Sign In
15 Sep 2011 14:42
ο»Ώ
For immediate release | 15 September 2011 |
ABCAM PLC
("Abcam" or "the Company")
Additional Listing
Β
Application has been made to AIM for the admission of 1,157,481 ordinary shares of 0.2p each in the Company to trading. These shares, which will rank pari passu in all respects with the existing shares in issue, have been allotted following the Company's acquisition of Ascent Scientific Limited announced on 13 September 2011. Settlement of this transaction is by way of a cash consideration of Β£6 million and Β£4 million of Abcam shares issued at 345.58p being derived from the rolling 25 day average price terminating three trading days prior to completion. Admission is expected to become effective on 19 September 2011.
Β
Β
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Β
Β
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its five operating companies.
Abcam now has an online catalogue of over 77,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Follow the stocks
